DEBRA LAING GRAYMAN, MD
7932 West Sand Lake Road, Suite 206
Orlando, Florida 32819
407-900-2580
Bachelor of Science in Microbiology, University of Florida Gainesville, Florida |
1993-1997 |
|
Doctor of Medicine, Morehouse School of Medicine Atlanta, Georgia |
1997-2001 |
|
Department of General Surgery, University Hospitals of Cleveland Cleveland, Ohio |
2001-2002 |
|
Residency |
||
Resident-Dermatology Department, St. Luke’s-Roosevelt Hospital Center New York, New York |
2003-2006 |
|
Certifications – Board and Other |
|
Diplomate, American Board of Dermatology |
|
Licensure |
|
Florida |
ME 98190 |
Employment |
|
Teaching Assistant, Morehouse School of Medicine – Department of Psychiatry Atlanta, Georgia |
1999-2000 |
Teaching Assistant, Morehouse School of Medicine – Department of Pathology Atlanta, Georgia |
1999-2000 |
Dermatologist, Debra Price, MD, PA Miami, Florida |
2007-2008 |
Dermatologist, Onsite Dermatology Boca Raton, Florida |
2008-2009 |
Dermatologist, Associates in Dermatology Orlando, Florida |
2009-2011 |
Dermatologist, Locum Tenens Staffing Companies Orlando, Florida |
2011-2012 |
Dermatologist / Medical Director, Pure Skin Dermatology & Aesthetics 7932 West Sand Lake Road, Suite 206, Orlando, Florida 32819 |
2012-Present |
Clinical Research / Medical Training |
|
CITI GCP On-line Course |
2019 |
Society Membership / Committees |
|
American Academy of Dermatology |
2003-Present |
Mentor Facial Filler Advisory Board |
2003 |
Women’s Dermatological Association |
2003-2006 |
Physicians United Plan, Medical Advisory Committee |
2012-2015 |
Alpha Kappa Alpha Sorority, Inc. – Psi Theta Omega Chapter |
2013-Present |
|
|
Speaker Experience |
|
Speaker, Amirall Speaker Program (Seysara) |
2019-2020 |
Speaker, Journey Medical Speaker Program (Ximino, Targadox, Accutane, Exelderm) |
2021-Present |
Speaker, Galderma Speaker Program (Epsolay) |
2022-Present |
Speaker, Galderma Acne & Rosacea Speaker Program |
March 2023-Present |
Arcutis Virtual Advisory Board |
April 2023 |
Speaker, Alma Academy Spring Forum |
May 2023 |
Incyte Dermatology Virtual Advisory Board |
May 2023 |
Affiliations |
|
Investigator, Accel Research Sites – Pure Skin Dermatology & Aesthetics 7932 West Sand Lake Road, Suite 206, Orlando, Florida 32819 |
2019-Present |
Investigator, Accel Research Sites – DeLand Clinical Research Unit 860 Peachwood Drive, DeLand, Florida 32720 |
2019-Present |
Accel Research Sites 615 Crescent Executive Court, Suite 120, Lake Mary, Florida, 32746 |
2020-Present |
Publications & Presentations |
Grayman DL, Alexis AR, Taylor SC. Central Centrifugal Cicatricial Alopecia: An Update. Manuscript in Progress. |
Groner A, Grayman D, Silverberg N. Outpatient Pediatric Community Associated MRSA: A Polymorphous Clinical Disease. Accepted for Publication in Cutis January 2008. |
Acne in Skin of Color: Issues and Approaches to Treatment. May 11, 2006. accessdermatology.com |
Presentation: An Unusual Presentation of Systemic Lupus Erythematosus in Pregnancy. Presented at American Academy of Dermatology Meeting. February 2004 |
Perez M, Grayman DL. Nonablative Laser Resurfacing. Cosmetic Dermatology. March 2005 |
Presentation: A Survey of the Knowledge, Attitudes, and Beliefs of Individuals Concerning Vaccinating their Children. Presented at a Research Symposium, Morehouse School of Medicine. October 1998 |
Presentation: A Survey of the Knowledge, Attitudes, and Beliefs of Individuals Concerning Vaccinating their Children. Presented at the NCID Research Symposium. July1998 |
Presentation: The Maroons: A Fight for Freedom. Ronald McNair Research Day. April 1997 |
Principal Investigator Clinical Research Experience |
|
Dermatology (Count: 7) |
|
Arcutis ARQ-151-302: A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis. |
2020 |
DermaSensor: DERMaSensor Use as an Adjunctive Tool in the ASSESSment of Skin Lesions Suggestive of Melanoma III (DERM-ASSESS III). |
2020 |
Pfizer B7451050: A Phase 3B Randomized, Double-Blind, Double-Dummy, Active |
2020 |
UCB HS0004: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects with Moderate to Severe Hidradenitis Suppurativa. |
2020 |
AbbVie – M15-999: This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel group study that will evaluate the safety and efficacy of the STUDY DRUG in patients with moderate to severe plaque psoriasis. |
2019 |
ChemoCentryx – CL016_168 (Aurora): A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa. |
2019 |
Xbiotech, Inc. – 2019-PT047: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa. |
2019 |
Sub-Investigator Clinical Research Experience |
|
Dermatology (Count: 3) |
|
Pfizer B7451015: A Phase 3 Multi-center, long-term extension study investigating the efficacy and safety of PF-04965842, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis. |
2019 |
Pfizer B7451036: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy and Safety of PF-04965842 Co-administered with Background Medicated Topical Therapy in Adolescent Participants 12 TO <18 Years of Age with Moderate to Severe Atopic Dermatitis. |
2019 |
Pfizer B7931023: A Phase 2B, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group, Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream Applied Once or Twice Daily for 12 Weeks in Participants with Mild to Moderate Chronic Plaque Psoriasis. |
2019 |